MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock remains negative
Q1 FY2026 common stock was $5K, compared with $0 a year earlier.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 5K USD
- Year-over-year change
- —
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Common Stock vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 common stock of $5K is the 7th highest of the 11 companies compared; the peer median is $12K.
- Common stock amounts to 0.0% of total assets for MPLT, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.55M | +0.0% | +6.0% | 0.6% | |
| Mar 2026 | $167K | +135.2% | +22.6% | 0.1% | |
| Dec 2025 | $93K | +9.4% | +3.7% | 0.1% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $48K | +29.7% | +15.7% | 0.0% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $18K | +12.5% | +78.3% | 0.0% |
| Mar 2026 | $6K | +20.0% | +26.0% | 0.0% | |
| Mar 2026 | $5K | — | — | 0.0% | |
| Jun 2026 | $4.72K | +575.7% | +100.9% | 0.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $3K | +200.0% | +44.2% | 0.0% |
| Mar 2026 | $3K | +0.0% | +44.2% | 0.0% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $0 | — | — | 0.0% |
| Peer median (excluding MPLT) | $12K | +20.0% | +26.0% | 0.0% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.